Switch View
© PR Newswire
03.11.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
Ambetter from Peach State Health Plan Offers Health Insurance in Georgia in 2026
News Preview
During open enrollment, starting Nov. 1, residents can access affordable Ambetter from Peach State Health Plan plans in 149 counties
ATLANTA, Nov. 3, 2025 /PRNewswire/ -- Ambetter from Peach State Health Plan, a product offered by a Centene Corporation (NYSE: CNC) company, a l...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US88033G4073
Tenet Healthcare Corp
THC
LISTED
NYSE
Tenet Announces Private Offerings of Senior Secured Notes and Senior Notes to Refinance $2.0 Billion in Outstanding Notes
News Preview
Tenet Healthcare Corporation (NYSE: THC) today announced private placement offerings of $1.5 billion in aggregate principal amount of new senior secured first lien notes due 2032 (the “first lien notes”) and $0.5 billion in aggregate principal amount of new senior notes due 2033 (the “senior notes” and together with the first lien notes, the “note...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
Baxter International, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before December 15, 2025 to Discuss Your Rights - BAX
News Preview
NEW YORK, Nov. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Baxter International, Inc. (NYSE: BAX).
Shareholders who...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
03.11.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
Lost Money on MoonLake Immunotherapeutics(MLTX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
News Preview
NEW YORK, Nov. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX).
Shareholders...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
03.11.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ATYR
News Preview
NEW YORK, Nov. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR).
Shareholders who purch...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
Shareholders that lost money on Savara Inc.(SVRA) should contact The Gross Law Firm about pending Class Action - SVRA
News Preview
NEW YORK, Nov. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA).
Shareholders who purchased s...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Class Action Filed Against Lantheus Holdings, Inc. (LNTH) Seeking Recovery for Investors - Contact The Gross Law Firm
News Preview
NEW YORK, Nov. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH).
Shareholders who...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
The Gross Law Firm Notifies Cytokinetics, Incorporated Investors of a Class Action Lawsuit and Upcoming Deadline - CYTK
News Preview
NEW YORK, Nov. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK).
Shareholders...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US5324571083
Eli Lilly and Co
LLY
LISTED
NYSE
Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide
News Preview
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
INDIANAPOLIS, Nov. 3, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufac...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US14149Y1082
Cardinal Health Inc
CAH
LISTED
NYSE
Cardinal Health completes acquisition of Solaris Health
News Preview
Adds the country's leading urology MSO with over 750 providers to Cardinal Health's leading multi-specialty MSO platform, The Specialty Alliance and brings Cardinal Health's MSO platforms to ~3,000 providers in 32 states
DUBLIN, Ohio, Nov. 3, 2025 /PRNewswire/...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US5324571083
Eli Lilly and Co
LLY
LISTED
NYSE
Lilly plans to build a new €2.6 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide
News Preview
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
INDIANAPOLIS, Nov. 3, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today plans to build a new €2.6 billion (3...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US5898891040
Merit Medical Systems Inc
MMSI
LISTED
NASDAQ
Merit Medical Releases 24-Month Efficacy Results from the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
News Preview
SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced 24-month efficacy findings from the non-randomized AVG cohort of the WAVE trial. Results of the AVG cohort were presented during the Late-Breaking Clinical Trials session at the annual VIVA Fo...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
03.11.2025
ISIN: US6024961012
MiMedx Group Inc
MDXG
LISTED
NASDAQ
MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule
News Preview
Company is Well Positioned to Continue to Compete and Grow Company is Well Positioned to Continue to Compete and Grow...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US57055L1070
Marker Therapeutics, Inc.
MRKR
LISTED
NASDAQ
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
News Preview
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US14070B3096
Capricor Therapeutics, Inc.
CAPR
LISTED
NASDAQ
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel
News Preview
–Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development– ...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US2300311063
Cullinan Therapeutics Inc
CGEM
LISTED
NASDAQ
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
News Preview
CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US87164F1057
Syndax Pharmaceuticals Inc
SNDX
LISTED
NASDAQ
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
News Preview
– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R inhibition –...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US87164F1057
Syndax Pharmaceuticals Inc
SNDX
LISTED
NASDAQ
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
News Preview
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 8, 2025, at 7:00 a.m. ET during the 67th American Society of H...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: IL0011595993
InMode Ltd.
INMD
LISTED
NASDAQ
InMode Appoints Michael Dennison as President of North America
News Preview
IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America. ...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US45773H4092
Inovio Pharmaceuticals Inc
INO
LISTED
NASDAQ
INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults
News Preview
Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need
INO-3107 previously received Orphan Drug and Breakthrough Therapy designations; BLA submitted under FDA's Acc...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US8808811074
Terns Pharmaceuticals Inc
TERN
LISTED
NASDAQ
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting
News Preview
Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: DK0010272202
Genmab A/S
GMAB
LISTED
CPH
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
News Preview
Media ReleaseCOPENHAGEN, Denmark; November 3, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US0197701065
Allogene Therapeutics Inc
ALLO
LISTED
NASDAQ
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that a Trial-in-Progress (TIP) poster highlighting the pivotal Phase 2 ALPHA3 tria...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US2210151005
Corvus Pharmaceuticals Inc
CRVS
LISTED
NASDAQ
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma will be presented in an oral session at the 67th American Society of Hematology (ASH) Ann...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US00847X1046
Agios Pharmaceuticals Inc
AGIO
LISTED
NASDAQ
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
News Preview
Agios today announced that new data on mitapivat, an oral pyruvate kinase activator, will be featured in oral and poster presentations during ASH...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US74065P1012
Prelude Therapeutics Inc
PRLD
LISTED
NASDAQ
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
News Preview
WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the publication of two abstracts with preclinical data on the Company’s JAK2V617F mutant selective inhibitors and CALR-targeted degrader antibody conjugates...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US9032141049
Cogent Biosciences, Inc.
COGT
LISTED
NASDAQ
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results
News Preview
Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
Ambetter of Oklahoma Offers Health Insurance in Oklahoma in 2026
News Preview
During open enrollment, starting Nov. 1, residents can access affordable plans from Ambetter of Oklahoma in 43 counties.
OKLAHOMA CITY, Nov. 3, 2025 /PRNewswire/ -- Ambetter of Oklahoma, a product offered by a Centene Corporation (NYSE: CNC) company, a leading healthcare enter...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US28036F1057
Edgewise Therapeutics Inc
EWTX
LISTED
NASDAQ
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
News Preview
BOULDER, Colo., Nov. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on October 31, 2025, Edgewise grant...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
Ambetter from Louisiana Healthcare Connections Offers Health Insurance in Louisiana in 2026
News Preview
During open enrollment, starting Nov. 1, residents can access affordable Ambetter from Louisiana Healthcare Connections plans in 22 parishes.
BATON ROUGE, La., Nov. 3, 2025 /PRNewswire/ -- Ambetter from Louisiana Healthcar...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US1011371077
Boston Scientific Corp
BSX
LISTED
NYSE
Boston Scientific announces upcoming investor conference schedule
News Preview
MARLBOROUGH, Mass., Nov. 3, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.
On November 18,...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: GB00BN4HT335
Indivior PLC
INDV
LISTED
NASDAQ
Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
News Preview
Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization
Adherence to SUBLOCADE was associated with lower rates of infectious disease compl...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
Ambetter of Tennessee Offers Health Insurance in Tennessee in 2026
News Preview
During open enrollment, starting Nov. 1, residents can access affordable
Ambetter of Tennessee plans statewide.
MEMPHIS, Tenn., Nov. 3, 2025 /PRNewswire/ -- Ambetter of Tennessee, a product offered by a Centene Corpor...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
Ambetter from Home State Health Offers Health Insurance in Missouri in 2026
News Preview
During open enrollment, starting Nov. 1, residents can access affordable Ambetter from Home State Health plans in 109 counties.
ST. LOUIS, Nov. 3, 2025 /PRNewswire/ -- Ambetter from Home State Health, a product offered by a Centene Corporation (NYSE: CNC) company, a leading hea...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
Ambetter from Superior HealthPlan and Ambetter Health Offer Health Insurance in Texas in 2026
News Preview
During open enrollment, starting Nov. 1, residents can access affordable plans from Ambetter from Superior HealthPlan in 150 counties.
AUSTIN, Texas, Nov. 3, 2025 /PRNewswire/ -- Ambetter from Superior HealthPlan and Ambetter Health, products offered by Centene Corporation (NYSE...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
Ambetter of Alabama Offers Health Insurance in Alabama in 2026
News Preview
During open enrollment, starting Nov. 1, residents can access affordable Ambetter of Alabama plans in 40 counties.
HUNTSVILLE, Ala., Nov. 3, 2025 /PRNewswire/ -- Ambetter of Alabama, a product offered by a Centene Corporation (NYSE: CNC) company, a leading healthcare enterpris...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
Ambetter from Sunflower Health Plan Offers Health Insurance in Kansas in 2026
News Preview
During open enrollment, starting Nov. 1, residents can access affordable Ambetter from Sunflower Health Plan plans in 91 counties.
LENEXA, Kan., Nov. 3, 2025 /PRNewswire/ -- For more than seven years, Ambetter from Sunflower Health Plan has helped Kansans access affordable,...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
Ambetter Health Offers Health Insurance in Nebraska in 2026
News Preview
During open enrollment, starting Nov. 1, residents can access affordable Ambetter Health plans statewide.
OMAHA, Neb., Nov. 3, 2025 /PRNewswire/ -- Ambetter Health, a product offered by a Centene Corporation (NYSE: CNC) company, a leading healthcare enterprise that provides ins...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US67080M1036
Nurix Therapeutics Inc
NRIX
LISTED
NASDAQ
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
News Preview
Nurix presents new data from bexobrutideg Ph 1a/1b clinical trial in patients with r/r CLL and updates in patients with WM at #ASH25...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US9032141049
Cogent Biosciences, Inc.
COGT
LISTED
NASDAQ
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting
News Preview
SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US36266G1076
GE Healthcare Technologies Inc
GEHC
LISTED
NASDAQ
GE HealthCare management to present at upcoming investor conference
News Preview
GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conference.
Jefferies Global Healthcare Conference in London, England – Tuesday, November 18, 2025 at 9:30 am GMT/4:30 am ET/3:30 am CT
A webcast of this event can be accessed at the GE HealthCare website: https://in...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US92764N1028
Vir Biotechnology Inc
VIR
LISTED
NASDAQ
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in patients with chronic hepatitis delta (CHD). ECLIPSE 1 is one of three trials in Vir Biotechnology’s ECLIPSE registrational program for CHD, and it is...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US90184D1000
Twist Bioscience Corp
TWST
LISTED
NASDAQ
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
News Preview
As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that it has granted a total of 139,569 equity awards, consisting of 91,441 restricted stock units (“RSUs”) and up to 48,128 performance stock units (“PSUs”), to 41...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US2975841048
Estrella Immunopharma, Inc.
ESLA
LISTED
NASDAQ
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
News Preview
Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the successful completion of the second dose cohort in Phase I portion of its STARLIGHT-1 Phase I/II clinical trial...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk
News Preview
Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware.
The lawsuit asserts that Novo Nordisk’s recent proposal to acquire Metsera constitutes an anticompetitive action by Novo Nordisk to protect its...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: CA71719L1067
Pharmala Biotech Holdings Inc.
MDMA
LISTED
CSE
PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital
News Preview
PharmAla files its final short form prospectus, and announces a signed term sheet with an R&D tax credit financing firm called Radium...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US31447E1055
Femasys Inc
FEMY
LISTED
NASDAQ
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
News Preview
-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured convertible notes for total potential proceeds of $58 million, if all warrants are exercised for cash, reflecting strong investor confidence in Femasys’ wo...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: AU000000AVH4
Avita Medical Inc.
AVH
LISTED
ASX
Data Presented at the 2025 Southern Region Burn Conference Reinforce RECELL® System as a Standard of Care in Acute Wound Treatment
News Preview
AVITA Medical data at SRBC 2025 confirms RECELL® as standard of care, improving healing, reducing hospital stays, and lowering treatment costs...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US0044685008
Achieve Life Sciences, Inc.
ACHV
LISTED
NASDAQ
Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation
News Preview
120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully ConcludedDSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US46266A1097
IRadimed Corp
IRMD
LISTED
NASDAQ
IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Results
News Preview
Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US1374041093
Candel Therapeutics, Inc.
CADL
LISTED
NASDAQ
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
News Preview
NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US14888U1016
Catalyst Pharmaceuticals Inc
CPRX
LISTED
NASDAQ
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference
News Preview
CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, Presiden...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US74168J1016
Prime Medicine Inc
PRME
LISTED
NASDAQ
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer
News Preview
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer (CBO). Dr. Hawryluk will lead Prime’s corporate and...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: CA60255C8850
Mind Medicine (MindMed) Inc
MNMD
LISTED
NASDAQ
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the closing of its previously announced underwritten public offering of 21,131,250 common shares, without par value, which includes the exerci...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ISIN: US92790C1045
Viridian Therapeutics Inc
VRDN
LISTED
NASDAQ
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
News Preview
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced the successful October submission of its BLA to the U.S. Food and Drug Administration (FDA) for veligrotug, the company’s investigational ther...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US63909J1088
Nautilus Biotechnology Inc
NAUT
LISTED
NASDAQ
Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging
News Preview
• Buck Institute’s deployment of Nautilus’ instrument generates tau proteoform data, providing external validation of the company’s next-generation single-molecule proteomics platform • Joint research results show high reproducibility across sites and insight into novel tau biology, signaling a fundamental shift in how proteomics technology can adv...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: IL0011316309
Mediwound Ltd
MDWD
LISTED
NASDAQ
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
News Preview
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US53635D2027
Liquidia Corp
LQDA
LISTED
NASDAQ
Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences
News Preview
MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that members of the company’s executive leadership team will be providing updates on the company's business during fireside chat...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: ES0167733015
Oryzon Genomics SA
ORY
LISTED
BME
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease
News Preview
MADRID and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical‑stage biopharmaceutical company and global leader in epigenetics, today announced that the first patient has been enrolled in RESTORE, its multi‑center, open‑label Phase Ib clinical trial of iadademstat in adults...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.11.2025
ISIN: US8693671021
Sutro Biopharma Inc
STRO
LISTED
NASDAQ
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th Annual World ADC Conference, taking place in San Diego, November 3-6, 2025....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
